AR108671A1 - Análogos de diamida imidodicarbonimidica - Google Patents
Análogos de diamida imidodicarbonimidicaInfo
- Publication number
- AR108671A1 AR108671A1 ARP170101515A ARP170101515A AR108671A1 AR 108671 A1 AR108671 A1 AR 108671A1 AR P170101515 A ARP170101515 A AR P170101515A AR P170101515 A ARP170101515 A AR P170101515A AR 108671 A1 AR108671 A1 AR 108671A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- alkyl
- heterocycloalkyl
- nr5r6
- Prior art date
Links
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical class NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 12
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000003107 substituted aryl group Chemical group 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 5
- 239000012453 solvate Substances 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- -1 -NR4R4 Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010036049 Polycystic ovaries Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud está dirigida a compuestos de diamida imidodicarbonimidica, y sus sales, solvatos o estereoisómeros farmacéuticamente aceptables. También proporciona composiciones y el uso de tales composiciones en métodos para tratar el cáncer, la diabetes o el síndrome de ovario poliquístico. Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) donde: cada R¹ es independientemente halógeno, -CN, -NO₂, -OR⁴, -NR⁴R⁴, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; p es 0, 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este. Reivindicación 18: Un compuesto de fórmula (2) donde: cada R¹ es independientemente halógeno, -CN, -NO₂, -OR⁴, -NR⁴R⁴, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; p es 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este. Reivindicación 34: Un compuesto de fórmula (3) donde: cada R¹ es independientemente halógeno, -CN, -NO₂, -NR⁴R⁴, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; n es 0 ó 1; p es 1, 2, 3 ó 4; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este. Reivindicación 51: Un compuesto de fórmula (4) donde: cada R¹ es independientemente -CN, -NR⁴R⁴, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; p es 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345708P | 2016-06-03 | 2016-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108671A1 true AR108671A1 (es) | 2018-09-12 |
Family
ID=60479127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101515A AR108671A1 (es) | 2016-06-03 | 2017-06-02 | Análogos de diamida imidodicarbonimidica |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR108671A1 (es) |
| WO (1) | WO2017210580A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254593A (en) * | 1984-03-19 | 1993-10-19 | The Rockefeller University | Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking |
| IL145957A0 (en) * | 1999-04-15 | 2002-07-25 | Fox Chase Cancer Ct | A pharmaceutical composition comprising an agent which binds with 3-deoxyglucosone |
| US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| US7256218B2 (en) * | 2002-11-22 | 2007-08-14 | Jacobus Pharmaceutical Company, Inc. | Biguanide and dihydrotriazine derivatives |
| WO2008093984A1 (en) * | 2007-01-29 | 2008-08-07 | Hanall Pharmaceutical Company. Ltd | N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| US9480663B2 (en) * | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US8796338B2 (en) * | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| KR101424667B1 (ko) * | 2011-08-08 | 2014-08-04 | 한올바이오파마주식회사 | Ｎ1-고리아민-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
-
2017
- 2017-06-02 AR ARP170101515A patent/AR108671A1/es unknown
- 2017-06-02 WO PCT/US2017/035720 patent/WO2017210580A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017210580A1 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095339A1 (es) | Compuestos moduladores alostericos de la hemoglobina | |
| AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| AR108010A1 (es) | Derivados de indolina y su uso como inhibidores de ews-fli1 | |
| AR097794A1 (es) | Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b | |
| AR102222A1 (es) | Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos | |
| AR096161A1 (es) | Derivados de triazina | |
| AR097795A1 (es) | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a | |
| AR108671A1 (es) | Análogos de diamida imidodicarbonimidica | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |